Thomson Reuters Corp (TRI.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Thomson Reuters Corp (TRI.TO)

127.04

+6.32 (5.24%)

as of Jul 24, 2026, 8:00:00 pm Market Open.

221 watching

Investor Insights

Jul 24, 2026, 12:00 am

This summary was created by AI, based on 36 opinions in the last 12 months.

Thomson Reuters Corp (TRI) has been experiencing significant scrutiny in the market due to concerns about the impact of artificial intelligence (AI) on its core businesses, particularly in the legal and accounting sectors. While many analysts acknowledge the company's strong financial fundamentals, including consistent topline growth and a robust balance sheet, fears surrounding AI's potential to disrupt their proprietary data remain prevalent. Opinions are divided; some believe TRI's unique data offerings will enable it to withstand AI-related challenges, while others express skepticism about the stock's future trajectory, given its previous high valuation and current trading multiples. Overall, the market sentiment towards TRI is cautious, indicating potential for both recovery and continued volatility in the stock's price as it navigates these AI-driven uncertainties.

Consensus

Cautious

Valuation

Fair Value

Similar

RELX, REL

BUY

Likes this company a lot. There has been gradually improving margins and asset turnover. Has a 95% probability that it outperforms the market.

TOP PICK

(A Top Pick Feb 14/06. Up 10.3%.) Looks at this as an information conglomerate and he likes conglomerates. The stock had formed a rounded base last year and broke out in the latter part. Under owned.

HOLD

A high-quality Canadian company that always enjoys really rich multiples. Shares are fully valued at this time.

PAST TOP PICK

(A Top Pick Oct 18/06. Up 6.1%.) Particularly likes this going into a slowing economy, because they sell information that people need.

DON'T BUY

Have been making a few acquisitions. Trades at a healthy price/earnings ratio.

SELL

There are better places to put your money.

BUY

Re-focusing and selling some pieces in order to be an e-business. Looking at 8% to 12% growth. High quality and pays a dividend.

DON'T BUY

This is a great company, but thinks the stock will continue to go sideways. Growth rate is rather anaemic and the multiple is extremely high.

BUY

Unloading their Learning Division for $5 billion. Likes their focus on new management.

TOP PICK

A very defensive company but has solid growth. Organic growth of 7 to 9%. Likely to increase the dividend at a 10% annual rate. In none economic sensitive areas.

TOP PICK

Starting to make substantial moves into engineering, sciences, etc besides their current legal and medical areas. Have been investing their capital into the new areas and it is starting to show results. Seeing consistent increases in revenues. ROE has been improving quarter after quarter.

DON'T BUY

Trades at a fairly lofty multiple. Showing modest growth. Trading on the more expensive side.

COMMENT

Really great company. Most of their earnings come out of the US so with earnings growth converted back to Cdn$, it has done nothing over the last few years. Internal growth has been 7%. Spending $300 million over the next 3 years to cut costs and will save $150 million a year. A little expensive.

BUY ON WEAKNESS

Has traditionally been more expensive on a price/earnings ratio than what he likes to pay. A first-rate company. The demand for information they supply will keep on growing. Would buy it at $40.

PAST TOP PICK

(A Top Pick Aug 2/05. Up 4%.) The story is very much intact and unfolding the way he expected. Starting to drive the values in synergies out of their acquisitions and starting to drive the earnings growth.

Showing 466 to 480 of 715 entries

Most Recent Experts

Andrew Pink

LDIC

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Thomson Reuters Corp (TRI.TO)